Analyst Price Target is $7.50
▲ +216.46% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MaxCyte in the last 3 months. The average price target is $7.50, with a high forecast of $9.00 and a low forecast of $6.00. The average price target represents a 216.46% upside from the last price of $2.37.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in MaxCyte. This Buy consensus rating has held steady for over two years.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Read More
